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Role of Oxidative Stress and Inflammatory Factors in 
Diabetic Kidney Disease
Esmat Aghadavod,1 Samaneh Khodadadi,2 Azar Baradaran,3 
Parto Nasri,4 Mahmood Bahmani,5 Mahmoud Rafieian-Kopaei6
Diabetic nephropathy (DN) is a serious complication of diabetes 
mellitus, and its prevalence has been increasing in developed 
countries. Diabetic nephropathy has become the most common single 
cause of end-stage renal disease (ESRD) worldwide. Oxidative stress 
and inflammation factors are hypothesized to play a role in the 
development of late diabetes complications. Chronic hyperglycemia 
increases oxidative stress, significantly modifies the structure and 
function of proteins and lipids, and induces glycoxidation and 
peroxidation. Therefore, hyperglycemia causes auto-oxidation of 
glucose, glycation of proteins, and activation of polyol mechanism. 
Overproduction of intracellular reactive oxygen species contributes 
to several microvascular and macrovascular complications of DN. 
On the other hand, reactive oxygen species modulates signaling 
cascade of immune factors. An increase in reactive oxygen species 
can increase the production of inflammatory cytokines, and likewise, 
an increase in inflammatory cytokines can stimulate the production 
of free radicals. Some studies have shown that kidney inﬂammation 
is serious in promoting the development and progression of 
DN. Inflammatory factors which are activated by the metabolic, 
biochemical, and hemodynamic derangements are known to exist 
in the diabetic kidney. This review discusses facts for oxidative 
stress and inﬂammatory factors in DN and encompasses the role 
of immune and inﬂammatory cells, inﬂammatory cytokines, and 
stress oxidative factors.
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INTRODUCTION
Diabetic nephropathy (DN) is considered as 
one of the main microvascular complications of 
diabetes mellitus (DM) and has become the most 
general single cause of end-stage renal disease 
(ESRD) worldwide.1-6 It is traditionally defined a 
progressive rise in urine albumin excretion together 
with increasing blood pressure, leading to declined 
glomerular filtration, and eventually ESRD.7-9 
It also is characterized by renal morphological 
and functional alterations such as glomerular 
hyperfiltration, glomerular and renal hypertrophy, 
increased urinary albumin excretion, increased 
basement membrane thickness, and mesangial 
expansion with the accumulation of extracellular 
matrix proteins such as collagens, fibronectin, and 
laminin.10-12
On the one hand, there are several risk factors 
for the development of DN, including duration of 
DM, age at diagnosis, race, systemic or glomerular 
hypertension, poor glycemic control, genetic 
predisposition to kidney disease, and dietary 
composition. On the other hand, oxidative stress 
and inflammatory factors are 2 serious elements 
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in promoting DN. Subsequently, nephropathy is 
a common microvascular complication among 
patients with type 2 DM and a major cause of 
chronic kidney disease.13-20
This review article discusses the pathophysiological 
mechanisms of renin-angiotensin system (RAS) 
inhibition by herbal plants. For this review, we 
used a variety of sources by searching through the 
Web of Science, PubMed, EMBASE, Scopus, and 
the Directory of Open Access Journals (DOAJ). The 
search was performed using combinations of the 
following key words and their equivalents: diabetic 
nephropathy, reactive oxygen species, chronic kidney 
disease, microalbuminuria, and advanced glycation 
end products.
PATHOGENESIS OF DIABETIC 
NEPHROPATHY
The development of DN has been described as a 
5-stage process: stage 1, progression of glomerular 
hyperfiltration and nephromegaly and an above-
normal glomerular filtration rate (GFR); stage 2, 
thickening of glomerular basement membrane 
and mesangial expansion, with GFR remaining 
elevated or returned to normal, but glomerular 
damage progressed to significant microalbuminuria 
(excreting more than 30 mg of albumin in urine 
over a 24-hour period); stage 3, progression of 
microalbuminuria (more than 300 mg of albumin 
in a 24-hour period), eventual decline in GFR 
and hypertension; stage 4, continued glomerular 
damage, overt proteinuria, increased blood urea 
nitrogen and creatinine, decreased GFR by about 
10% annually with severe hypertension and 
squeal of moderate to severe renal insufficiency; 
and stage 5, fibrosis, sclerosis, decreased GFR to 
approximately 10 mL/min, and eventual ESRD.13-20
PATHOPHYSIOLOGY PATHWAYS
There are different pathways such as formation of 
advanced glycation end products, polyol pathway, 
hexosamine pathway, protein kinase C pathway, 
growth factors, cytokines, and free radicals that 
have been reported to play an important role in 
DN.20-22
Advanced Glycation End-products Pathways
Hyperglycemia has generally been considered 
as the key initiator of kidney damage, which can 
act by activation and dysregulation of several 
metabolic pathways. Some evidence demonstrates 
that advanced glycation end products (AGEs) play 
a pivotal role in the development and progression 
of diabetic vascular damage. Additionally, diabetic 
patients with ESRD had almost twice as much AGEs 
in the kidneys as diabetic patients without kidney 
disease. Accumulation of AGEs in the kidney may 
contribute to the progressive alteration in and 
loss of kidney function in the patients. Advanced 
glycation end products contribute to a variety of 
microvascular and macrovascular complications 
through the formation of cross-links between 
molecules in the basement membrane of the 
extracellular matrix and by engaging the receptor 
for advanced glycation end products.23-25 Therefore, 
AGEs can alter intracellular signaling, gene 
expression, release of pro-inflammatory molecules, 
and free radicals. Consequently, increasing levels 
of AGEs support the formations of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) 
which in turn induce further formation of AGEs. 
On the other hand, AGEs formation can connect 
with key molecules in the basement membrane of 
the extracellular matrix (ECM), including lipids, 
collagen, laminin, elastin, and vitronectin; therefore, 
formation of AGEs on ECM molecules alters the 
constitution of the matrix,both matrix-matrix and 
cell-matrix interactions, being involved in signaling 
pathway of diabetic glomerulosclerosis.26-30
The main site for reabsorption of filtered AGEs 
is proximal tubule of kidney. Accumulation of 
AGEs in the kidney can induce transforming 
growth factor (TGF)-β gene expression possibly via 
protein kinase C (PKC) or oxidative stress pathway. 
Some studies show oxidative stress is increased 
in proportion to the accumulation of AGEs; also, 
these compounds can lead to enhanced formation 
of free radicals 25,28
Based on recent evidence, AGEs and carbonyl 
intermediates contribute to the generation of 
superoxide from mitochondrial system; therefore, 
AGEs contribute to the release of pro-inflammatory 
cytokine and expression of growth factors such as 
TGF-β, insulin-like growth factor 1, platelet-derived 
growth factor, tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β, and IL-6.30,31
Polyol Pathway
Increasing the amount of nonconsumption glucose 
induces polyol pathway, which can increase AGEs 
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formation and oxidative stress factors. Therefore, 
hyperglycemia can induce polyol pathway flux.32-34 
The polyol pathway consists of 2 enzymes: aldose 
reductase that reduces glucose to sorbitol with 
assistance of its cofactor nicotinamide adenine 
dinucleotide phosphate (NADPH), and sorbitol 
dehydrogenase (SDH) that converts sorbitol to 
fructose with assistance its co-factor NAD+. These 
enzymes decrease the ratio of NADPH/NADP and 
increase the ratio of NADH/NAD; thus, these may 
result in both oxidative stress and activation of 
PKC. Based on evidence, NADPH acts as a cofactor 
for glutathione reductase, which is significant for 
equilibrium of ROS. On the other hand, sorbitol 
cannot diffuse easily across cell membranes and 
it induces osmotic damage to microvascular cells. 
Generally, it is suggested that increased flux of 
glucose metabolism through the polyol pathway 
can induce activation of PKC, reduction of NADPH, 
and amplification of ROS.35-38
Hexosamine Pathway
Excessive intracellular glucose can induce 
activation of hexosamine pathway, in which 
fructose-6-phosphate is diverted from glycolysis 
to glucosamine-6-phosphate and other substrates 
for reactions that require uridine diphosphate 
-N-acetylglucosamine.  Based on evidence, 
glutamine-fructose-6-phosphate amidotransferase 
(GFAT) is the rate-limiting enzyme of this pathway. 
Both high glucose and angiotensin II activates the 
GFAT promoter in mesangial cells. Increasing of 
glucose metabolism flux through the hexosamine 
pathway can induce overexpression of GFAT gene 
in mesangial cells that to enhances both TGF-β and 
fibronectin expression. Although the mechanism 
by which overexpression is induced is uncertain, it 
has been supposed the mechanism is by increased 
N-acetylglucosamine that may covalently modify 
transcription factors and signaling molecules. Also, 
N-acetylglucosamine can activate PKC and all 
factors which are associated with the development 
of DN.39-41
Protein Kinase C Pathway
Protein kinase C is activated by excessive 
diacylglycerol, lipid second messenger, which is 
formed from glyceraldehyde-3-phosphate. Based 
on evidence, hyperglycemia can induce increased 
amount of diacylglycerol in cultured microvascular 
cells and in the retina and renal glomeruli of diabetic 
animals.42-45 In the kidney, PKC activation can reduce 
production of nitric oxide by endothelial nitric oxide 
synthase; therefore, it leads to changes in renal 
blood flow, mesangial expansion, albuminuria and 
increased GFR, increased pro-inflammatory gene 
expression, and vascular permeability.5,9 Also, PKC 
activation may be responsible for the amplified 
expression of ECM molecules both directly and 
through TGF- β1overexpression. Some studies 
show that PKC activation induces expression of the 
permeability-enhancing factor vascular endothelial 
growth factor (VEGF) in smooth muscle cells, which 
contributes to increased microvascular matrix 
protein accumulation by inducing expression 
of TGF-β, fibronectin, and type IV collagen. In 
addition, PKC activation has also been implicated 
in the overexpression of the fibrinolytic inhibitor 
plasminogen activator inhibitor-1, activation of 
nuclear factor-κB in cultured endothelial cells and 
vascular smooth muscle cells.42,46
Growth Factors and Cytokines
Hyperglycemia  s t imulates  res ident  and 
nonresident renal cells to produce several growth 
factors, cytokines, chemokines, and vasoactive 
agents that implicate to the development of kidney 
injury. Growth factors which are involved in the 
development of DN include VEGF, Platelet Derived 
Growth Factor, Connective Tissue Growth Factor 
(CTGF), and insulin-like growth factor.46-52
Transforming Growth Factor-β
Tumor growth factor B, a profibrogenic cytokine, 
which controls synthesis and degradation of 
extracellular matrix proteins by stimulating 
transcription of ECM genes in renal cells and 
reducing collagenase production, eventually plays a 
central role in the development of renal hypertrophy 
and accumulation of ECM components. Therefore, 
monocytes, macrophages, and macrophages are 
filtrated into glomeruli and they release growth 
factors and cytokines that may contribute to 
promotion of glomerular growth.53
There is increasing evidence that factors such as 
hyperglycemia, AGEs, endothelin, and products of 
oxidative stress regulate TGF-β gene expression in 
renal cells. Also, it is obvious that intrarenal RAS 
is activated in DN. In fact, angiotensin II stimulates 
TGF-β gene expression in renal cells by molecular 
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mechanism. Therefore, enhanced expression of 
angiotensin II receptors and deceased degradation 
of angiotensin II involved in many biological 
processes that local effects of angiotensin II which 
acts in synergy with hyperglycemia in stimulating 
free radicals can induce renal hypertrophy and 
synthesis of ECM proteins.40,44
Connective Tissue Growth Factor
Connective tissue growth factor has been 
described as a marker and a mediator of DN. 
Synthesis of CTGF is stimulated by hyperglycemia, 
AGEs, and TGF-β . Connective tissue growth 
factor induces mesangial cell hypertrophy and 
cytoskeletal disassembling and upregulates cell 
production of fibronectin and collagens.45 Also, 
CTGF is an important mediator of the profibrotic 
activity of TGF-β.
Vascular Endothelial Growth Factor
Vascular EndothelialGrowth Factor is a potent 
inducer of vasopermeability and angiogenesis 
that plays a major pathophysiological role in DN. 
Serum levels of VEGF associate with albuminuria 
and increase with DN stage. Several studies have 
confirmed that VEGF may contribute to some of 
the hemodynamic alterations in DN, including 
hyperfiltration and albuminuria. Expression of 
VEGF is modulated by high glucose, endothelin 
1, AGEs, angiotensin II, and TGF-β. Also, VEGF 
can affect podocyte function and involves in 
macrophage influx into glomeruli.44,46
Oxidative Stress
Reactive oxygen species, such as superoxide or 
hydroxyl, are byproducts of oxygen metabolism that 
play a major part in cell signaling and degenerative 
disease processes. Naturally, the quantity of 
ROS produced is balanced with the anti-oxidant 
activity including, superoxide dismutase, catalase, 
and glutathione peroxidase that are required for 
neutralizing its adverse effects. Therefore, ROS is 
continuously generated but effectively eliminated 
by antioxidant activity system. Imbalance of ROS 
generation with antioxidant system can alter 
essential cellular proteins or DNA.37,38 Also, ROS 
generation may be increased through multiple 
mechanisms including increased polyol pathway, 
AGEs formation, NADPH oxidase and activation 
of PKC. Nicotinamide adenine dinucleotide 
phosphate oxidase is the main source of ROS in 
the mesangial cells, smooth cells, and endothelial 
cells. Hyperglycemia induces oxidative stress that 
increases generation of ROS or diminishes the 
production of antioxidants that can lead to increased 
oxidant-derived tissue injury.35 Some evidence 
show high glucose can induce activation of PKC 
in diabetic glomeruli through de novo synthesis 
of diacylglycerol. Also, PKC produces ROS which 
in turn causes activation of PKC thereby causing 
augmentation of mesangial expansion, basement 
membrane thickening, and dysfunctionof endothelial 
cells, leading to DN.18-20 Hyperglycemia activates 
isoforms of nicotinamide adenine dinucleotide 
phosphate oxidases, especially nicotinamide adenine 
dinucleotide phosphate oxidases-4 that induces ROS 
formation thereby leads to endothelial dysfunction, 
inflammation, and apoptosis.39,40
Furthermore, it has been found that ROS activates 
PKC, mitogen activated protein kinase, NADPH 
oxidase, and nuclear factor-κB, and upregulates 
TGF-β1 and fibronectin levels; thus, production of 
ROS in DN can induce renal tissue injury. Therefore, 
enhanced level of TGF-β leads to renal hypertrophy, 
glomerulosclerosis, and tubulointerstitial fibrosis 
in DN.47-49
Some studies suggest that VEGF, a protein factor 
secreted by the podocytes and the mesangial cells 
of the kidney, plays an important function in the 
progression of DN. In oxidative stress condition, 
VEGF gene expression is increased by the activity 
of hypoxia-inducible factor that interferes with 
the phosphoinositide 3-kinase/protein kinase 
B pathway and modulates the expression of 
endothelial nitric oxidesynthase. Therefore, VEGF 
ultimately elevates the level of intracellular ROS 
by stimulating the generation of peroxynitrite. In 
addition, VEGF leads to theproteinuria thereby 
adding complications to DN.46,50
Consequently, hyperglycemia increases the 
inflammatory activities by activating macrophages 
follow by enhances ROS productionleading the 
way to DN. Some evidences show excessive 
ROS production by different pathways leads to 
the activation of downstream molecules such as 
p38 mitogen activated protein kinases, nuclear 
factor-κB, and TGF-β  pathways.  Generally, 
hyperglycemia elevates intracellular ROS by 
many converging pathwaysand finally leads to 
nephropathic situation by activating an arrayof 
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diverging signaling cascades. Also, ROS-regulated 
signaling pathways lead to accumulation of ECM 
in the kidney tissue.21,37,48
Inflammation Cells and Inflammatory Factors
From the beginning of stages of DN, macrophages 
and T cells accumulate in the glomeruli and 
inters t i t ium.  Act ivated macrophages ,  key 
inflammatory cells of the kidney, elaborate a host of 
pro-inflammatory, pro-fibrotic, and antiangiogenic 
factors. These macrophage-derived products include 
TNF-α, IL-1, IL-6, ROS, plasminogen activator 
inhibitor-1, matrix metalloproteinases, TGF-β, 
platelet-derived growth factor, angiotensin II, and 
endothelin.32-34 Hyperglycemia induces macrophage 
accumulation and activation that can deposit 
glomerular immune complex, increase chemokine 
production, and progressive fibrosis. Some evidence 
show kidney macrophage accumulation is strongly 
associated with the degree of glomerular sclerosis, 
creatinine serum levels, proteinuria, and interstitial 
fibrosis. Monocyte chemoattractant protein 1, a key 
cytokines involved in macrophage migration into 
the diabetic kidney, is significantly increased in DN. 
Some studies suggest that renal chemoattractant 
protein 1 is also correlated with proteinuria.3,8,47,48
Lymphocytes
T cells can also infiltrate into diabetic kidneys, and 
their function is better characterized in crescentic 
glomerulonephritis, for instance antiglomerular 
basement membrane disease. In diabetic patients, 
T cell influx into kidney correlates with altered 
kidney function and albuminuria. Some evidence 
note T cells accumulate in the juxtaglomerular 
apparatus although; the functional role of T cells 
in this compartment is unclear.5,9,11
Intercellular adhesion molecule (ICAM)-1, a 
glycoprotein involved in attachment of leukocytes to 
endothelium, associates with leukocyte infiltration 
and disease progression in diabetic patients. 
Intercellular adhesion molecule-1 expression is 
induced by factors such as hyperglycemia, AGEs, 
and andoxidative stress, but it can also be increased 
by additional elements such as hyperlipidemia, 
hyperinsulinemia, and elevated levels of circulating 
TNF-α. Also, it is demonstrated that intercellular 
adhesion molecule-1 is  a  cr i t ical  mediator 
ofmacrophage accumulation in diabetic kidneys 
both in early and late stages of diabetes.4,10,46
Tumor necrosis factor-α is generally produced 
by monocytes, macrophages, and T cells. Also, it 
can be generated by resident renal cells including 
mesangial, glomerular, endothelial, dendritic, and 
renal tubular cells. Tumor necrosis factor-α induces 
production of local ROS, increasing albumin 
permeability, induction of cytotoxicity, apoptosis, 
and necrosis. Some studies demonstrate patients 
with type 2 diabetes have 3 to 4 times greater 
serum levels of TNF-α compared to nondiabetic 
patients. The amount of TNF-α serum levels is 
correlated with microalbuminuria in diabetic 
patients. However, TNF-α is a clinical markers of 
DN and progression of disease.47-49
Interleukin-1 induces expression of chemotactic 
factors and adhesion molecules, enhances vascular 
endothelial permeability, and stimulates the 
proliferation of mesangial cells. Some studies 
demonstrate IL-1 increases endothelial cell 
permeability and alters glomerular hemodynamics 
by affecting prostaglandin synthesis therefore; it 
can stimulate mesangial and fibroblast proliferation. 
Interleukin-1 levels correlate with albuminuria and 
end-stage kidney disease.18-22,52
Interleukin 6 is a pleiotropic cytokine secreted 
by endothelial cells, leukocytes, adipocytes, and 
mesangial cells. It can affect extracellular matrix 
dynamics in renal cells and enhances endothelial 
permeability.53 Serum IL-6 levels have a significant 
correlation with severity of diabetic glomerulopathy, 
kidney hypertrophy, and albumin excretion thus 
suggested a role for IL-6 in the pathogenesis of 
DN. It has been suggested that IL-6 mediates 
endothelial permeability, mesangial proliferation, 
and increased fibronectin expression.53
Interleukin-18
Interleukin-18, a potent inflammatory cytokine, 
induces interferon-γ expression and the production 
of other pro-inflammatory cytokines such as IL-1 
and TNF-α. Also, it upregulates intercellular 
adhesion molecule-1 in endothelial cells. Some 
studies demonstrate tubular epithelial cells, 
infiltrating monocyte-macrophages and T cells are 
the major sources of IL-18. It is revealed serum and 
urinary IL-18 levels increase in DN and correlate 
with microalbuminuria. In addition, there is a 
positive association between serum IL-18 levels 
with urinary excretion of beta-2 microglobulin (a 
marker of tubulointerstitial injury).54-58
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CONCLUSIONS
Diabetic nephropathy has been described as a 
progressive increase in urine albumin excretion 
together with increasing blood pressure, leading 
to declined glomerular filtration and finally ESRD. 
The development of DN has been described as a 
5-stage process. There are different pathways such 
as formation of advanced glycation end products, 
polyol pathway, hexosamine pathway, protein 
kinase C pathway, growth factors, cytokines, and 
free radicals that play an important role in creation 
and progression of diabetic nephropathy, according 
to latest studies.
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